Announcements Trials
Browse Landscape Eligibility

Clinical Trials

2 trials
RecentStart dateEnrollment
KB004 × Clear all

Phase

Phase 1/2 1Phase 1 1

Status

Suspended 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1CNS 1

Conditions

Primary Myelofibrosis 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia 1Glioblastoma 1

Interventions

Cisplatin 3176Cyclophosphamide 3172Carboplatin 2955Radiotherapy 2771Paclitaxel 2705Gemcitabine 2549pembrolizumab 2368Bevacizumab 2192Docetaxel 2190Fluorouracil 1837Capecitabine 1815Oxaliplatin 1723Dexamethasone 1592Nivolumab 1575Doxorubicin 1500Rituximab 1480Magnetic Resonance Spectroscopy 1365Etoposide 1341Irinotecan 1240Leucovorin 1215Drug Therapy 1189Cytarabine 1126Pemetrexed 1067fludarabine 1035Specimen Handling 985Vincristine 964Prednisone 940Cetuximab 938Trastuzumab 936Lenalidomide 932

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements
NCT03374943 2021-11-04

A Trial of KB004 in Patients With Glioblastoma

Olivia Newton-John Cancer Research Institute

Phase 1 Completed
12 enrolled
CNS

Glioblastoma

NCT01211691 2015-11-17

Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)

Humanigen, Inc.

Phase 1/2 Suspended
120 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡